Bokf, Na Annovis Bio, Inc. Transaction History
Bokf, Na
- $5.59 Billion
- Q1 2025
A detailed history of Bokf, Na transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Bokf, Na holds 555 shares of ANVS stock, worth $1,159. This represents 0.0% of its overall portfolio holdings.
Number of Shares
555
Previous 555
-0.0%
Holding current value
$1,159
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ANVS
# of Institutions
53Shares Held
2.08MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA648KShares$1.35 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$347,3970.0% of portfolio
-
Ubs Group Ag161KShares$336,2300.0% of portfolio
-
Geode Capital Management, LLC Boston, MA153KShares$318,9610.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$266,9030.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $17.1M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...